Vizsgálati helyszín
Oncology Hematology Care
Cincinnati, Ohio 45242, Egyesült ÁllamokMég nincs intézményhez kötve
- 15futó vizsgálat
- 7lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 22 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis10 vizsgálat
- 2. fázis8 vizsgálat
- 1. fázis2 vizsgálat
- Állapot
- Toboroz8 vizsgálat
- Fut, nem toboroz6 vizsgálat
- Lezárult4 vizsgálat
- Visszavonták2 vizsgálat
- Meghívásos bevonás1 vizsgálat
- Leállították1 vizsgálat
- Fő szponzor
- Janssen Research & Development, LLC5 vizsgálat
- SCRI Development Innovations, LLC3 vizsgálat
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company2 vizsgálat
- TScan Therapeutics, Inc.2 vizsgálat
- Allotera Therapeutics1 vizsgálat
- és még 9
Futó vizsgálatok
Toboroz
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06852222· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)
NCT06773910· 2. fázis· SCRI Development Innovations, LLC· Forrás
Toboroz
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
NCT06646276· 3. fázis· Bristol-Myers Squibb· Forrás
Contact: Patrick Ward, Site 0284
Toboroz
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
NCT06514794· 2. fázis· Allotera Therapeutics· Forrás
Contact: Doug Hart
Toboroz
APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML
NCT06634394· 1. fázis· Aptevo Therapeutics· Forrás
Contact: Research Coordinator
Fut, nem toboroz
A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
NCT05963074· 2. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
NCT05973487· 1. fázis· TScan Therapeutics, Inc.· Forrás
Toboroz
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06297226· 2. fázis· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Forrás
Contact: Kruti Patel, Site 0054
Toboroz
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
NCT05972135· 2. fázis· SCRI Development Innovations, LLC· Forrás
Contact: Sarah Cannon Development Innovations, LLC
Fut, nem toboroz
A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors
NCT05812027· TScan Therapeutics, Inc.· Forrás
Toboroz
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
NCT05727904· 3. fázis· Iovance Biotherapeutics, Inc.· Forrás
Contact: Iovance Biotherapeutics Study Team
Toboroz
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
NCT05552222· 3. fázis· Janssen Research & Development, LLC· Forrás
Meghívásos bevonás
Long-Term Follow-up Study
NCT05332054· Caribou Biosciences, Inc.· Forrás
Fut, nem toboroz
Avelumab Program Rollover Study
NCT03815643· 3. fázis· EMD Serono Research & Development Institute, Inc.· Forrás
Fut, nem toboroz
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
NCT02811861· 3. fázis· Eisai Inc.· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Toboroz
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
NCT06974786· 2. fázis· SCRI Development Innovations, LLC· Forrás
Contact: Sarah Cannon Development Innovations, LLC
Visszavonták
A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies
NCT06205290· 3. fázis· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Forrás
Lezárult
A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations
NCT04083976· 2. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
NCT03901963· 3. fázis· Janssen Research & Development, LLC· Forrás
Leállították
Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma
NCT03646123· 2. fázis· Seagen Inc.· Forrás
Lezárult
A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma
NCT03274492· 3. fázis· Hoffmann-La Roche· Forrás
Lezárult
A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
NCT02975934· 3. fázis· pharmaand GmbH· Forrás
Hibát jelzek